Dermatology Therapy Treatments 
Nutritional Aesthetics Alliance
MARCH 10, 2024
Like most skin conditions, acne doesn’t have just one cause or one treatment that will work–it can be complicated. We also touched on the importance of an integrative approach that includes diet, lifestyle, and mindset, alongside topical treatments. 00:11:17] Teenage acne treatment approaches. [00:12:55]
Dermatology Times
AUGUST 2, 2024
Michele Ramien, MD, discusses biologic therapies for pediatric dermatology, focusing on their impact on vaccines, managing side effects, and tailoring treatment.
The Dermatology Digest
APRIL 7, 2024
A newly developed therapeutic ladder can help guide dermatologists and patients on the use of nonsteroidal treatment options for atopic dermatitis (AD). Nonsteroidal treatment options for AD have rapidly expanded in recent years with the development of phosphodiesterase-4 inhibitors, biologics, and Janus kinase (JAK) inhibitors.
The Dermatology Digest
AUGUST 29, 2024
Food and Drug Administration (FDA)-approved therapies for scarring alopecia, and existing treatments are often ineffective, which is why many patients turn to complementary and alternative therapies. For the study, researchers conducted a literature review on alopecia and complementary treatments. One case study.
The Dermatology Digest
FEBRUARY 8, 2024
The Dermatology Digest asked key thought leaders and editorial advisory board members to take out their crystal balls and weigh in on what’s to come in 2024 and beyond. Inside the Burgeoning AD Pipeline AD is another dermatologic condition that is undergoing a transformation in terms of treatment options and paradigms.
Dermatology Times
FEBRUARY 8, 2024
However, any dermatology provider who has prescribed one quickly learns of the immense barriers surrounding them. Biologics represent the pinnacle of scientific progress, engineered to precisely target conditions previously deemed untreatable.
The Dermatology Digest
FEBRUARY 20, 2024
Lifileucel is the first tumor-infiltrating lymphocyte therapy, or TIL, approved for solid tumors. “The approval of Amtagvi represents the culmination of scientific and clinical research efforts leading to a novel T cell immunotherapy for patients with limited treatment options.”
Expert insights. Personalized for you.
195 
Let's personalize your content